In December 2007 Shire announced its Board succession plans. Dr James H Cavanaugh will retire as Non-Executive Chairman; Matthew Emmens will succeed him as Non-Executive Chairman; and Angus Russell will be appointed as Chief Executive Officer. Shire is now working to identify a replacement Chief Financial Officer to ensure an orderly succession. These Board changes will become effective at Shire's AGM in June 2008, at which time David Kappler will be appointed as Deputy Chairman in addition to his existing role as Senior Independent Director.
Shire would like to thank the Hon. James Grant Q.C. for his contributions during six years of service.
Changes in Senior Management
In September 2007 Shire appointed Sylvie Gregoire as President of its HGT business.
Notes to editors
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com
The "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a
number of risks and unce
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved